Tonix Pharmaceuticals Appoints Ganesh Kamath as Head of Market Access
Mr. Kamath brings over 25 years of extensive experience in market access, pricing, and commercial operations to Tonix Pharmaceuticals. His appointment, effective September 29, 2025, is aimed at strengthening Tonix’s leadership as it prepares for the launch of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia.
Significant Experience in Market Access
Previously, Mr. Kamath served as the Vice President of Financial Planning & Analysis, Business Development, and Sales Operations at CuriaGlobal. His role there involved executing strategic initiatives that immensely bolstered business development and operational efficacy. Before joining Curia, he was the Senior Vice President and Chief Financial Officer at Hutchmed International, where he successfully implemented pricing governance frameworks and enhanced market access strategies.
“Ganesh brings invaluable expertise and a proven track record from prestigious organizations like Bayer HealthCare and Hutchmed International,” stated Thomas Englese, EVP Commercial of Tonix Pharmaceuticals. His leadership is expected to ensure patient access to Tonix’s therapies and promote operational efficiency within the company.
Preparing for the Launch of Tonmya™
With the anticipated market entry of Tonmya™, which was recently approved for fibromyalgia treatment, Kamath is poised to unlock significant commercial potential. “Joining Tonix during this critical phase allows me to contribute to the successful launch of Tonmya™ for fibromyalgia patients,” he remarked.
Tonmya™ is notably the first new treatment for fibromyalgia in over 15 years, marking a pivotal moment for those affected by this chronic pain condition. The company is geared towards a fourth quarter launch in the U.S., signaling a new chapter for both Tonix and fibromyalgia treatment.
Tonix Pharmaceuticals’ Broad Portfolio
Tonix Pharmaceuticals is more than just Tonmya™; it is a fully-integrated biotechnology company with a robust pipeline of drug candidates and existing marketed products. The company focuses extensively on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases.
Among its promising drug candidates, TNX-102 SL is in development for acute stress reaction and disorder, supported by studies through institutions like the University of North Carolina. In immunology, the development of biologics for conditions such as organ transplant rejection and various autoimmune diseases continues, with products like TNX-1500 demonstrating the company’s commitment to addressing critical healthcare needs.
Commitment to Research and Development
Additionally, Tonix is engaged in various R&D initiatives, including a push towards infectious disease solutions. Its vaccine candidate TNX-801 aims to combat mpox and smallpox, showcasing Tonix’s commitment to addressing significant public health threats.
The company operates a state-of-the-art research facility in Frederick, Md., emphasizing its dedication to advancing healthcare through innovation.
Frequently Asked Questions
Who is Ganesh Kamath?
Ganesh Kamath is the newly appointed Head of Market Access for Tonix Pharmaceuticals, with extensive experience in the pharmaceutical industry.
What is Tonmya™?
Tonmya™ is a recently FDA-approved treatment for fibromyalgia, marking an important advancement in therapies for this condition.
What role does Ganesh Kamath play at Tonix Pharmaceuticals?
As Head of Market Access, Kamath will focus on ensuring patient access to Tonix’s therapies and enhance the operational strategies relating to pricing and contracting.
What is the focus of Tonix Pharmaceuticals?
Tonix Pharmaceuticals is a biotechnology company dedicated to developing treatments for central nervous system disorders, immunology, immuno-oncology, and rare diseases.
Where is Tonix Pharmaceuticals based?
Tonix Pharmaceuticals is based in the United States and operates a cutting-edge research facility in Frederick, Maryland.
